Go Deep
Syncom Formulations (India) Limited
Syncom Formulations (India) Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,241 | 26.5 | 5.65 | 0.00 | 24.94 |
| Oct 2026 | 21,122 | 24.8 | 5.27 | 0.00 | 23.28 |
Syncom Formulations (India) Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,255,264,000.0 | 1,354,118,000.0 | 1,151,406,000.0 | 1,217,174,000.0 |
| Net Profit | 248,468,000.0 | 251,744,000.0 | 189,081,000.0 | 166,011,000.0 |
| EPS | 0.3 | 0.3 | 0.2 | 0.2 |
Syncom Formulations (India) Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 4,816,895,000.0 | 4,573,731,000.0 | 2,592,440,000.0 | 2,224,861,000.0 |
| Net Profit | 764,380,000.0 | 494,346,000.0 | 253,142,000.0 | 200,707,000.0 |
| EPS | 0.8 | 0.5 | 0.3 | 0.2 |
Syncom Formulations (India) Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 5,338,452,000.0 | 4,132,807,000.0 | 4,046,640,000.0 | 3,778,305,000.0 | — |
| Total Liabilities | 1,188,569,000.0 | 711,231,000.0 | 1,165,212,000.0 | 1,218,158,000.0 | — |
| Total Equity | 4,149,883,000.0 | 3,421,576,000.0 | 2,881,428,000.0 | 2,560,147,000.0 | — |
Owes vs Owns
Syncom Formulations (India) Limited owed ₹0.22 for every ₹1 it owned in Mar 2026, down from ₹0.32 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.22× | 0.17× | 0.29× | 0.32× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Syncom Formulations (India) Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 21.1%Receivables 20.7%Inventory 11.8%Fixed assets (tangible) 17.0%Long-term investments 3.2%Other assets 26.1%
How it's funded — Mar 2026
Payables 13.9%Other liabilities 8.0%Shareholders' equity 77.7%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 112.6 | 89.9 | 131.5 | 70.8 |
| Receivables | 110.5 | 107.5 | 103.3 | 75.5 |
| Inventory | 62.9 | 41.3 | 21.1 | 21.2 |
| Fixed assets (tangible) | 90.8 | 78.1 | 72.5 | 70.6 |
| Intangible assets | 0.4 | 0.0 | 0.1 | 0.2 |
| Long-term investments | 17.3 | 16.2 | 3.5 | 73.2 |
| Other assets | 139.4 | 80.2 | 72.7 | 66.4 |
| Liabilities & equity | ||||
| Short-term debt | 1.5 | 4.6 | 72.5 | 83.2 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 74.4 | 44.1 | 24.1 | 20.4 |
| Other liabilities | 43.0 | 22.4 | 19.9 | 18.2 |
| Shareholders' equity | 415.0 | 342.2 | 288.1 | 256.0 |
| Net tangible assets | 414.6 | 342.1 | 288.0 | 255.8 |
Syncom Formulations (India) Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 580,793,000.0 | 234,361,000.0 | -59,583,000.0 | 105,293,000.0 | — |
| Investing Activities | -506,227,000.0 | -182,042,000.0 | 830,196,000.0 | -449,527,000.0 | — |
| Financing Activities | -30,211,000.0 | -679,033,000.0 | -145,576,000.0 | 350,014,000.0 | — |